Chief, Interventional Cardiology

University of California San Francisco

Printed as of 4/25/2024

## **Disclosures**

#### Personal Commercial (6)

Company Name	Relationship Category Compensation Level		Topic Area(s)	
Self				
Abbott Laboratories	Research/Research Grants	Significant (>= \$5,000)	Valvular Heart Disease	
Cardiovascular Research Foundation	Data Safety Monitoring Board Modest (< \$5,000)		Valvular Heart Disease	
Edwards Lifesciences	Consultant Fees/Honoraria Significant (>= \$5,000)		Valvular Heart Disease	
Edwards Lifesciences	Research/Research Grants	Significant (>= \$5,000)	Valvular Heart Disease	
Edwards Lifesciences	nces Research/Research Grants \$\frac{\tau}{\text{Evaluation of the Identification and Management}}\$ of Severe Aortic Stenosis within a Large Academic Health System		Valvular Heart Disease	
Medtronic	ronic Research/Research Grants  ‡ HALT Biomarker Study		Valvular Heart Disease	

# Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

# Personal Organizational or Other Non-Commercial (0)

No disclosures on record

### Clinical Trial Enroller (4)

Trial Name	Trial Sponsor	Trial Funding Source
REPAIR MR	Abbott Laboratories	
CLASP IITR	Edwards Lifesciences	
TRISCEND II Trial	Edwards Lifesciences	
CLASP IIF	Edwards Lifesciences	

### Institutional Financial Decision-Making Role (0)

No disclosures on record

## **Expert Witness Testimony (1)**

Year	Case Title	Represented	Description	Compensation
Self				
2020	STEMI & aplastic anemia	Defendant † Ratcliffe Harten Galamaga LLP	Patient with aplastic anemia & STEMI and treated with DAPT/heparin prior to PCI c/b ICH.	Significant (>= \$5,000)

† Commercial Funding Source | ‡ Trial Name

### **Agreement**

### Certified Education Attestation | Signed on 8/25/2023

URL for full agreement: http://disclosures.acc.org/Public/Definition/Certified Education Attest at ion Agreement to the property of the

### Confidentiality, Disclosure and Assignment Agreement | Signed on 8/25/2023

URL for full agreement: http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement

Embargo | Signed on 8/25/2023

URL for full agreement: http://disclosures.acc.org/Public/Definition/EmbargoAgreement

### On-Going Obligation Agreement | Signed on 8/25/2023

### **ACC and Disclosures**

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.